3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
5
Breast Neoplasms
5
Stomach Neoplasms
3
Neoplasms
2
Esophageal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Biliary Tract Neoplasms
2
Triple Negative Breast Neoplasms
1
Sarcoma
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Muscle Invasive Bladder Cancer (MIBC)
1
Hemangiosarcoma
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Gallbladder Neoplasms
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Transitional Cell
1
Interventions
Gemcitabine
26
Capecitabine
16
Oxaliplatin
14
Fluorouracil
13
Cisplatin
12
Leucovorin
9
pembrolizumab
5
Erlotinib Hydrochloride
5
Bevacizumab
5
durvalumab
4
Trastuzumab
4
Specimen Handling
4
Sorafenib
4
Magnetic Resonance Spectroscopy
4
130-nm albumin-bound paclitaxel
4
trifluridine tipiracil drug combination
3
Lapatinib
3
Irinotecan
3
Carboplatin
3
Biopsy
3
tremelimumab
2
toripalimab
2
regorafenib
2
lenvatinib
2
dehydroftorafur
2
cobimetinib
2
atezolizumab
2
anlotinib
2
Nivolumab
2
N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Gallbladder Neoplasms
×
zanidatamab
×
Clear all
NCT04466891
2025-09-15
HERIZON-BTC-01
Jazz Pharmaceuticals
Phase 2
Completed
87 enrolled
25 charts
1 FDA